Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study
暂无分享,去创建一个
R. Marcus | D. Wrench | P. Fields | S. Devereux | D. Yallop | P. Patten | S. Bowcock | S. Kassam | Vijayavalli Dhanapal | M. Gunasekara | Chia Lianwea | C. De Lord
[1] L. Belayachi,et al. Efficacy of the GemOx‐R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma , 2016, British journal of haematology.
[2] M. Gleeson,et al. Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐GEM‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma , 2015, European journal of haematology.
[3] P. Galan,et al. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma , 2014, OncoTargets and therapy.
[4] Bingshu E. Chen,et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Horwich,et al. GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma , 2014, Annals of Hematology.
[6] P. Gaulard,et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial , 2013, Haematologica.
[7] S. Montoto,et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Iannitto,et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma , 2009, Cancer Chemotherapy and Pharmacology.
[10] Jordi Martínez,et al. GEMOX‐R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large‐cell lymphoma: a phase II study , 2007, European journal of haematology.
[11] C. Copie-Bergman,et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Gascoyne,et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[15] A. Norman,et al. An oxaliplatin‐based chemotherapy in patients with relapsed or refractory intermediate and high‐grade non‐Hodgkin's lymphoma , 2001, British journal of haematology.
[16] B. Debuire,et al. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[18] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.